Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab

Med J Aust. 2021 Nov 1;215(9):435. doi: 10.5694/mja2.51303. Epub 2021 Oct 7.

Authors

Ashish Srinivasan^{1

2}, Craig Haifer^{3

4}, Lena Thin⁵

Affiliations

¹ Eastern Health, Melbourne, VIC.
² Monash University, Melbourne, VIC.
³ St Vincent's Hospital Sydney, Sydney, NSW.
⁴ University of Sydney, Sydney, NSW.
⁵ Fiona Stanley Hospital, Perth, WA.

PMID: 34622467
DOI: 10.5694/mja2.51303

No abstract available

Keywords: Medicolegal; Pharmaceuticals.

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal / adverse effects
Australia
Biosimilar Pharmaceuticals* / adverse effects
Humans
Inflammatory Bowel Diseases* / drug therapy
Infliximab / adverse effects

Substances

Antibodies, Monoclonal
Biosimilar Pharmaceuticals
Infliximab